Lexeo Therapeutics (LXEO) Conference February 06, 2025 01:30 PM ET Company Participants Debjit Chattopadhyay - Managing DirectorKyle Rasbach - CFOSandi See Tai - Chief Development Officer Debjit Chattopadhyay Alright. Good afternoon, and thank you for joining Guggenheim Therapeutics team, on our second Smith Gap Conference. I am Devjit, one of the therapeutic analysts. And joining me on stage from Lexio Therapeutics are Sandy C. Sai, chief development officer, and Kyle Raschbach, CFO. Thank you for making t ...

Centessa Pharmaceuticals (CNTA) Conference February 06, 2025 01:00 PM ET Company Participants Debjit Chattopadhyay - Managing DirectorMario Accardi - President of the Orexin Program Debjit Chattopadhyay Good afternoon, and thank you for joining Guggenheim's second, Smithcap conference. I am Devchit, and joining me from Syntesa is Mario Carty, the president of the Orexin program. Did I get that right? Mario Accardi You did. Yes, Doug. Hi. Great to be here with you. Debjit Chattopadhyay Well, it's been a very ...

Protagonist Therapeutics (PTGX) Update / Briefing February 06, 2025 10:30 AM ET Speaker0 Good morning, everybody. Thanks for joining us. I'm Corey Davis with LifeSci Advisors. Welcome to our PV Day with Protagonist Therapeutics to review the current PV market and set the stage for the upcoming Phase III data that are expected in March. We have got two KOLs and a number of company executives to walk through what I hope will be a scintillating presentation. We've got about 40 people in the room and over 100 p ...

Arqit Quantum (ARQQ) Update / Briefing February 06, 2025 10:00 AM ET Company Participants Andy Leaver - CEO Conference Call Participants Scott Buck - Managing Director & Senior Technology Analyst Scott Buck morning, everyone. My name is Scott Buck. I'm a Technology Research Analyst here at H. C. Wainwright. I want to welcome everyone joining us for our conversation with Artec Quantum Chief Executive Officer, Andy Lieber. Before we get started, I want to read through the company's Safe Harbor statements. Ple ...

Kymera Therapeutics (KYMR) Conference February 06, 2025 10:00 AM ET Company Participants Nello Mainolfi - Co-Founder, President, CEO & Director Conference Call Participants Michael Schmidt - Senior Managing Director & Equity Research Analyst - Biotechnology Michael Schmidt Michael Schmidt, senior biotic analyst with Guggenheim, and I'd like to welcome, Nelo Manolfi, the founder, president, and CEO of Chimera to this next fireside chat. Nelo, welcome and thanks for joining us. Nello Mainolfi Thanks, Michael, ...

Phathom Pharmaceuticals (PHAT) Conference February 06, 2025 10:00 AM ET Company Participants Azmi Nabulsi - Co-Founder & COOMartin Gilligan - Chief Commercial Officer Conference Call Participants Yatin Suneja - Biotechnology Research Analyst Yatin Suneja Good morning, everyone. My name is Yatin Suneja. I am one of the biotech analysts here at Guggenheim. It is my pleasure to welcome our next presenting company, Fathom, to our SMITCAP Biotech Conference. We have a few members here from the company. We have M ...

Dianthus Therapeutics (DNTH) Conference February 06, 2025 09:00 AM ET Company Participants Marino Garcia - President, CEO, Secretary & Director Conference Call Participants Yatin Suneja - Biotechnology Research Analyst Yatin Suneja Good morning, everyone. My name is Yatin Suneja, one of the biotech analysts here at Guggenheim. Welcome to our SMITCAP Biotech Conference. It is my pleasure to introduce our our first presenting company of the day, Dianthus. From the company, we have Marino Garcia, who is the Ch ...

Tarsus Pharmaceuticals (TARS) Conference February 06, 2025 09:00 AM ET Company Participants Eddie Hickman - Vice PresidentJeff Farrow - CFO Eddie Hickman Good morning, everyone. Welcome back to the twenty twenty five Guggenheim's MidCap Biotech Conference. My name is Eddie Hickman and I'm one of the analysts here. I'm joined here by Tarsus Pharmaceutical CFO, Jeff Ferro. Thank you for being here, Jeff. Exciting year for Tarsus, the launch of Extemvy and the recent announcement of a new product and another n ...

纪要涉及的公司 The Buckle (BKE) [1] 纪要提到的核心观点和论据 - **销售数据** - 2025年2月1日结束的四周可比门店销售额同比增长4.4% [1] - 2025年2月1日结束的四周总净销售额为5950万美元，较去年同期五周的7260万美元下降18% [1] - 男装业务2025年2月1日结束的四周总销售额同比下降2.5%，占当月总销售额的46.5%，去年同期为50.5%，价格点上涨约0.5% [1][2] - 女装业务2025年2月1日结束的四周总销售额同比增长14%，占当月总销售额的53.5%，去年同期为49.5%，价格点上涨约4.5% [2] - 男女装类别中，配饰销售额同比增长约10%，鞋类销售额同比下降约7.5%，分别占1月净销售额的10%和4.5%，去年同期均为9.55% [3] - **运营数据** - UPT同比下降约3%，平均交易价值略有增加 [3] - 截至2025年，公司在42个州经营440家零售店，去年同期为444家 [4] 其他重要但是可能被忽略的内容 - 公司政策是不提供当前销售指引或预测下一季度业绩 [4] - 评论中的前瞻性陈述存在重大风险和不确定性，公司未来业绩和财务结果可能与陈述有重大差异 [4] - 如有进一步问题可致电Tom Heacock（308 - 238 - 2443）或Adam Akerson（308 - 338 - 2779） [5]

Costco Wholesale (COST) 2025 Update / Briefing February 05, 2025 04:00 PM ET Company Participants Josh Dahmen - Assistant Vice President of Financial Planning & Investor Relations Josh Dahmen Hello. I'm Josh Damon, AVP of Finance and Investor Relations, and I will review our sales results for the four week retail month of January, which started on Monday, January 6 and ended on Sunday, February 2. This period is compared to the four weeks that began last year on Monday, January 8 and ended on Sunday, Februa ...